Stay updated on PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo

Sign up to get notified when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.
Latest website image capture
Clouds background image

Latest updates to the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page

  1. Check
    yesterday
    Change Detected
    Summary
    The page’s revision label was updated to v3.5.4, replacing the previous v3.5.3, indicating an incremental update to the page’s versioning. This is an internal metadata change and does not modify the study content or how information is presented to users.
    Difference
    0.0%
    Check dated 2026-05-15T05:50:09.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page’s interface revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a release change to the site software rather than any modification to the study record content.
    Difference
    0.0%
    Check dated 2026-04-24T05:54:21.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:38:41.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Version v3.5.0 has been added and version v3.4.3 has been removed.
    Difference
    0.0%
    Check dated 2026-03-19T06:00:06.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-12T02:27:51.000Z thumbnail image
  8. Check
    94 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the previous funding notice and Revision: v3.4.1.
    Difference
    0.3%
    Check dated 2026-02-11T11:35:58.000Z thumbnail image

Stay in the know with updates to PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo

Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.